Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled Trial

NCT06093191 is registered in ClinicalTrials.gov with Jin-Fu Xu as lead sponsor.

NCT NCT06093191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06093191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled Trial
Lead sponsor
Jin-Fu Xu
Phase
Phase 4
Overall status
Completed
Start date
October 18, 2023
Completion date
November 15, 2025
Enrollment
371 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis adult, pseudomonas aeruginosa infection